☰

Global

COMUNICADO: IMBRUVICA®? de Janssen aprobado para el tratamiento de la macroglobulinemia de Waldenström (y 3)


    1) Ibrutinib licence. European Commission.

    2) Garcia-Sanz R, Ocio EM. Novel treatment regimens for Waldenström's

    macroglobulinemia. Expert Rev Hematol. 2010;3:339-50.

    3) European Medicines Agency. Committee for Medicinal Products for Human Use: Summary of

    opinion. Disponible

    en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003791/WC500170191.pdf

    . Ultima consulta en julio de 2015.

    4) American Cancer Society. Detailed guide: Waldenström macroglobulinemia. Disponible

    en: http://www.cancer.org/acs/groups/cid/documents/webcontent/003148-pdf.pdf Ul

    tima consulta en julio de 2015.

    5) Leukemia and Lymphoma Society. Waldenström macroglobulinemia facts. Disponible

    en:http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/waldenstrommacroglobulinemia.pdf

    . Ultima consulta en julio de 2015.

    6) Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol. 2007;138:700-20.

    7) Buske C, Leblond V, Dimopoulos M, et al. Waldenström's macroglobulinaemia: ESMO

    Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann

    Oncol. 2013;24(Suppl. 6):vi155-vi159.

    8) Yang G, Xu L, Zhou Y, et al. Participation of BTK in MYD88 signaling in malignant

    cells expressing the L265P mutation in Waldenström's macroglobulinemia, and effect on

    tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway

    inhibitors. J Clin Oncol. 2012;30(Suppl.):abstract 8106.

    9) O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly

    patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an

    open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48-58.

    10) Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's

    macroglobulinemia. N Engl J Med. 2015;372:1430-40.

    11) European Medicines Agency. How is the medicine expected to

    work? http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/

    0[6]/human_orphan_001058.jsp&mid=WC0b01ac058001d12b

    [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/06/human_orphan_001058.jsp&mid=WC0b01ac058001d12b ]

    . Ultima consulta en julio de 2015.

     

    Consultas a medios: 

    Natalie Buhl 

    Móvil: +353(0)85-744-6696 

    E-mail: nbuhl@its.jnj.com

     

     

    Relaciones para inversores: 

    Lesley Fishman 

    Tel: +1-732-524-3922 

    Louise Mehrotra 

    Tel: +1-732-524-6491 

     

     

    PHEM/IBR/0615/0008 

    Julio de 2015 

     

         (Logo:  http://photos.prnewswire.com/prnh/20140324/NY88746LOGO )

    Photo:

    http://photos.prnewswire.com/prnh/20140324/NY88746LOGO 

    Video:

    http://www.multivu.com/players/uk/7571151-janssen-waldenstrom-macroglobulinemia